Actively Recruiting

Age: 18Years - 71Years
All Genders
ID07123038

A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic

Led by Sonoma Biotherapeutics, Inc. · Updated on 2026-04-16

36

Participants Needed

10

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

This long-term follow-up observational study is designed to assess the safety of a gene-modified regulatory T cell (Treg) therapeutic in individuals who have previously received this treatment. It focuses on evaluating the type, severity, and possible causes of delayed adverse events over an extended period. The study enrolls adults aged 18 to 71 who have been treated in earlier clinical trials involving the gene-modified Treg therapy. Participants will undergo safety monitoring procedures including completing health questionnaires, routine physical exams, and reviews of medical history and medication use. Biospecimens such as blood and tissue samples will be collected at scheduled visits to detect any delayed adverse events related to the prior cell therapy. The study is planned to last up to 15 years following the initial dose received in parent treatment protocols. Throughout the study, participants will attend visits according to a set schedule for assessments and monitoring. Researchers will measure the incidence of delayed adverse events possibly linked to the gene-modified Treg therapeutic and track persistence of the therapy, replication competent lentivirus incidence, and mortality. The study's long duration allows careful observation of safety outcomes related to the treatment over time.

CONDITIONS

Brief Title

A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic

Who Can Participate

Age: 18Years - 71Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Previously received at least one dose of a Sonoma Biotherapeutics gene-modified Treg therapeutic in a prior treatment protocol
  • Understands the purpose and risks of the study and is willing to provide written informed consent
  • Willing to comply with all study procedures during the follow-up period
Not Eligible

You will not qualify if you...

  • Participation is not in the subject's best interest, as determined by the Investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Long-term Monitoring

Duration - Up to 15 years

Participants who have previously received a gene-modified regulatory T cell therapeutic are observed for up to 15 years to evaluate safety, including monitoring for delayed adverse events, health status, and collecting biospecimens as appropriate.

Scheduled visits according to the study assessment schedule

Trial Site Locations

Total: 10 locations

1

UCSF Medical Center

San Francisco, California, United States, 94143

Actively Recruiting

2

Stanford Medical Center

Stanford, California, United States, 94305

Actively Recruiting

3

University of Colorado

Aurora, Colorado, United States, 80045

Actively Recruiting

4

Northwestern University

Chicago, Illinois, United States, 60611

Actively Recruiting

5

Tufts University

Boston, Massachusetts, United States, 02111

Actively Recruiting

6

Massachusetts General Hospital

Boston, Massachusetts, United States, 02114

Actively Recruiting

7

Brigham and Women's Hospital

Boston, Massachusetts, United States, 02115

Actively Recruiting

8

University of Minnesota

Minneapolis, Minnesota, United States, 55455

Not Yet Recruiting

9

Duke University

Durham, North Carolina, United States, 27708

Not Yet Recruiting

10

The University of Texas MD Anderson Cancer Center

Houston, Texas, United States, 77030

Not Yet Recruiting

Loading map...

Research Team

S

Sabrina Fox-Bosetti, MPH

J

Jason Do

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Similar Trials

1726-nm Laser (AviClear) for Hidradenitis Suppurativa (HS): ...

Hidradenitis Suppurativa (HS)

Actively Recruiting

1 location

An Exploratory Clinical Study of YTS109 Cell Therapy in Adul...

Systemic Lupus Erythematosus (SLE)

Actively Recruiting

1 location

A Randomized, Double Blind, Placebo-Controlled, Dose Respons...

Rheumatoid Arthritis (RA)

Actively Recruiting

11 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here